CBI

Leading life science success

CBI is Israel’s largest life sciences holding company

about cbi

Clal Biotechnology Industries (TASE: CBI) is Israel’s leading life sciences investment company. CBI supports life sciences by identifying and powering science backed ventures and proactively guiding them to transform the healthcare industry.

portfolio

The CBI portfolio is comprised of biotechnology and medical device companies developing breakthrough solutions for serious unmet medical needs, while offering substantial value and investment potential.

+

MediWound

MediWound (Nasdaq: MDWD) is a specialty biotechnology company focused on the fields of severe burn and chronic wound management.
+

Gamida Cell

Gamida Cell is a cell and immune therapy visionary. Lead product, NiCord® is currently in phase III clinical trial in hematological malignancies.
+

Anchiano (formerly Biocancell)

Anchiano Therapeutics (TASE: ANCN) is a clinical stage biopharmaceutical company dedicated to developing new therapies for non-muscle-invasive bladder cancer.
+

Elicio

Elicio develops platform technologies to deliver agents directly to the antigen-presenting cells of the lymph nodes with many potential applications in cancer
+

Neon Therapeutics

Neon Therapeutics (Nasdaq: NTGN) is a clinical stage, immuno-oncology company focused on developing novel therapeutics leveraging neoantigen biology to treat cancer.
+

Cadent Therapeutics

Cadent Therapeutics is developing novel drugs for neurological and psychiatric disorders.
+

Exithera

eXIthera Pharmaceuticals is a clinical stage biotech company focused on discovering and developing Factor XIa inhibitors for the prevention of stroke and thrombosis.
+

Biokine

Biokine Therapeutics is company focused on developing novel therapeutics to treat cancer. It's lead product, BL-8040, is licensed to BiolineRx and is in phase III clinical development.

See complete portfolio

Press Releases

2019

08

Dec

Biokine: BioLineRx Announces that a Combination of BL-8040, KEYTRUDA® and chemotherapy show high level of disease control in metastatic pancreatic cancer phase IIa trial
17

Nov

MediWound: After 12 Months of Follow-Up, NexoBrid’s Safety, Cosmesis and Function Data in the U.S. Phase 3 Trial (DETECT) are comparable to Standard of Care
17

Nov

Anchiano Discontinues Phase 2 Codex Study of Inodiftagene in Non-Muscle-Invasive Bladder Cancer; Will Focuse on Advancing Pan-RAS Inhibitors
10

Nov

Neon Therapeutics Announces Updated Data from the NT-001 Clinical Trial of NEO-PV-01
06

Nov

Biokine: BioLineRx Announces BL-8040 in Combination with KEYTRUDA Shows Clinical Activity in Heavily Pretreated Metastatic Pancreatic Cancer Patients
22

Oct

Cadent Therapeutics Provides Clinical Update and Announces the Appointment of a Chief Medical Officer

Read all Press Releases